Skip to content
Clinical Trials – home

Mbal Za Zhensko Zdrave Nadezhda OOD

Research site

Bulgaria Blaga Vest Street 3, 1330 Sofia, Bulgaria

  • 10 trials recruiting
  • Breast cancer · Breast cancer metastatic · Non-small cell lung cancer
  • Adults and children

About Specializations

Mbal Za Zhensko Zdrave Nadezhda OOD in Sofia, Bulgaria specialises in clinical trials of conditions such as Breast cancer, Breast cancer metastatic, Non-small cell lung cancer, Hormone receptor positive HER2 negative breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, focusing on innovative treatments for solid tumors. The ongoing studies aim to enhance the understanding and management of these complex conditions.

  • Solid Tumor Management
  • Immunotherapy Advancements
  • Patient Safety and Tolerability

Through the Avelumab Program Rollover Study, the center is dedicated to monitoring the safety and tolerability of avelumab, providing critical insights into its long-term use in patients with solid tumors.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Blaga Vest Street 31330 SofiaBulgaria
Recruiting now
10 trials
Conditions studied
19

More sites in SofiaBulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

22 clinical trials

Cachexia

Recruiting

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Visugromab
  • Sponsor:CatalYm GmbH

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Adenomyosis

Recruiting

A study to evaluate the effect of valproic acid in women of reproductive age with adenomyosis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Ibuprofen
  • Sponsor:CCDRD Cooperative Clinical Drug Research and Development AG

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Pfizer Inc.

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:Relay Therapeutics Inc.

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Pfizer Inc.
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Ponsegromab
  • Sponsor:Pfizer Inc.

Endometriosis

Not recruiting

Study on the Effectiveness and Safety of OG-6219 and Naproxen Sodium for Women Aged 18-49 with Moderate to Severe Endometriosis Pain

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:FOR-6219
  • Sponsor:Organon LLC
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.